Leap Therapeutics (LPTX) Stock Price, News & Analysis

Company Overview

Leap Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Leap’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies. In addition to DKN-01, Leap is advancing preclinical programs that target novel pathways involved in cancer cell signaling and immune regulation, with the aim of identifying complementary assets for future clinical development.

Founded in 2016 and headquartered in Irvine, California, Leap Therapeutics completed its initial public offering in 2019 and trades on the NASDAQ under the ticker LPTX. The company conducts clinical trials in the United States and collaborates with academic and industry partners to accelerate its development programs. Michael Stoll, M.D., serves as President and Chief Executive Officer, overseeing a team of experienced professionals in oncology drug discovery and development.

Key Stats

• Today's Range: $0.48 to $0.52
• 50-Day Range: $0.24 to $0.76
• 52-Week Range: $0.22 to $4.79
• Volume: 718,095 shs
• Average Volume: 2.30 million shs
• Market Capitalization: $20.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.38
• Consensus Rating: Reduce

Leap Therapeutics Stock Analysis - MarketRank™

Leap Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 440th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Leap Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Leap Therapeutics has a consensus price target of $3.38, representing about 593.0% upside from its current price of $0.49.

Amount of Analyst Coverage

Leap Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Leap Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Leap Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Leap Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Leap Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.82% of the float of Leap Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Leap Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Leap Therapeutics has recently decreased by 33.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Leap Therapeutics does not currently pay a dividend.

Dividend Growth

Leap Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.82% of the float of Leap Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Leap Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Leap Therapeutics has recently decreased by 33.62%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.69

News Sentiment

Leap Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Leap Therapeutics this week, compared to 1 article on an average week.

Search Interest

21 people have searched for LPTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.50% of the stock of Leap Therapeutics is held by insiders.

Percentage Held by Institutions

Only 30.46% of the stock of Leap Therapeutics is held by institutions.

LPTX Stock Analysis - Frequently Asked Questions

How have LPTX shares performed this year?

Leap Therapeutics' stock was trading at $2.88 at the beginning of 2025. Since then, LPTX shares have decreased by 83.1% and is now trading at $0.4870.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.11.

When did Leap Therapeutics' stock split?

Shares of Leap Therapeutics reverse split on the morning of Wednesday, June 21st 2023.The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Leap Therapeutics' major shareholders?

Top institutional shareholders of Leap Therapeutics include Simplify Asset Management Inc. (2.35%) and Key Client Fiduciary Advisors LLC (0.33%).
View institutional ownership trends.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Leap Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Vaxart (VXRT) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPTX
• CIK: 1509745
• Web: www.leaptx.com
• Phone: (617) 714-0360
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Leap Therapeutics: $3.38
• High Price Target: $5.50
• Low Price Target: $1.25
• Potential Upside/Downside: +545.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -237.65%
• Return on Assets: -155.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.34
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 41,440,000
• Free Float: 38,332,000
• Market Cap: $21.66 million
• Optionable: Optionable
• Beta: -0.05